JERUSALEM, Israel, March 12, 2013 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, announced today that the company has acquired breakthrough Quickool technology enabling individuals to self-administer pain free injections.
SafeCode Drug Technologies acquired Quickool and EasyJet technology from Sindolor Medical Ltd., an Israel-based medical technologies development company.
The technologies enable individuals to safely and painlessly administer injections or blood lancing, by quickly cooling the site of the injection immediately prior to the piercing of the skin. The technology is particularly useful for patients with diabetes who need to test blood-sugar levels or inject themselves regularly with insulin.
In addition, the technology has several other useful applications. SafeCode intends to publish additional announcements regarding Quickool and EasyJet technologies in the coming months.
"The acquisition of additional marketable technologies adds significant value to SafeCode's existing product line," said Joel Klopfer, Chief Executive Officer of SafeCode Drug Technologies. "SafeCode's voice activated technology simplifies the administration of prescription medication, and the technology acquired from Sindolor Medical provides similar benefit."
"Making the administration of medicines and blood tests easier and painless has the potential to save lives, by reducing the chances of potentially life-threatening errors," Klopfer added.
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
SOURCE Safecode Drug Technologies Corp.